CL2007003042A1 - Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte - Google Patents
Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arteInfo
- Publication number
- CL2007003042A1 CL2007003042A1 CL200703042A CL2007003042A CL2007003042A1 CL 2007003042 A1 CL2007003042 A1 CL 2007003042A1 CL 200703042 A CL200703042 A CL 200703042A CL 2007003042 A CL2007003042 A CL 2007003042A CL 2007003042 A1 CL2007003042 A1 CL 2007003042A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation procedure
- naftalen
- tetrahidro
- piperazine
- piperidine
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 239000002253 acid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06122817 | 2006-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007003042A1 true CL2007003042A1 (es) | 2008-05-02 |
Family
ID=37885794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200703042A CL2007003042A1 (es) | 2006-10-24 | 2007-10-23 | Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8114880B2 (es) |
| EP (1) | EP2076494B1 (es) |
| JP (1) | JP5506085B2 (es) |
| KR (1) | KR101415536B1 (es) |
| CN (1) | CN101528695B (es) |
| AR (1) | AR063517A1 (es) |
| AT (1) | ATE475648T1 (es) |
| AU (1) | AU2007310925B2 (es) |
| BR (1) | BRPI0717357A2 (es) |
| CA (1) | CA2664141C (es) |
| CL (1) | CL2007003042A1 (es) |
| CY (1) | CY1111010T1 (es) |
| DE (1) | DE602007008124D1 (es) |
| DK (1) | DK2076494T3 (es) |
| EA (1) | EA016311B1 (es) |
| IL (1) | IL198332A (es) |
| JO (1) | JO2653B1 (es) |
| MX (1) | MX2009004386A (es) |
| NO (1) | NO20092005L (es) |
| NZ (1) | NZ575615A (es) |
| PL (1) | PL2076494T3 (es) |
| PT (1) | PT2076494E (es) |
| SI (1) | SI2076494T1 (es) |
| TW (1) | TWI396688B (es) |
| UA (1) | UA99109C2 (es) |
| WO (1) | WO2008049806A1 (es) |
| ZA (1) | ZA200902822B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| EP2076487B1 (en) * | 2006-10-24 | 2010-05-26 | Janssen Pharmaceutica N.V. | Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| SMT201700533T1 (it) * | 2010-10-18 | 2018-01-11 | Cerenis Therapeutics Holding Sa | Composti, composizioni e metodi utili per la mobilitazione del colesterolo |
| MX364895B (es) | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| DK3484528T3 (da) | 2016-07-18 | 2021-02-15 | Janssen Pharmaceutica Nv | Tau-pet-billeddannelsesligander |
| WO2019221192A1 (ja) * | 2018-05-15 | 2019-11-21 | 旭化成株式会社 | アミノ酸アミノアルキルエステル又はその無機酸塩の製造方法 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| WO2024006701A1 (en) * | 2022-06-28 | 2024-01-04 | Stepan Company | Method for making dialkyl amino acid ester sulfonates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| CA2272719C (en) | 1996-11-27 | 2002-10-01 | Pfizer Limited | Apo b-secretion/mtp inhibitory amides |
| GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| DE19963235A1 (de) * | 1999-12-27 | 2001-07-05 | Boehringer Ingelheim Pharma | Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| FR2816940A1 (fr) * | 2000-11-23 | 2002-05-24 | Lipha | Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation |
| EP2076487B1 (en) | 2006-10-24 | 2010-05-26 | Janssen Pharmaceutica N.V. | Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
-
2007
- 2007-10-03 JO JO2007410A patent/JO2653B1/en active
- 2007-10-22 JP JP2009533800A patent/JP5506085B2/ja not_active Expired - Fee Related
- 2007-10-22 CA CA2664141A patent/CA2664141C/en not_active Expired - Fee Related
- 2007-10-22 AU AU2007310925A patent/AU2007310925B2/en not_active Ceased
- 2007-10-22 WO PCT/EP2007/061286 patent/WO2008049806A1/en not_active Ceased
- 2007-10-22 DE DE602007008124T patent/DE602007008124D1/de active Active
- 2007-10-22 NZ NZ575615A patent/NZ575615A/en not_active IP Right Cessation
- 2007-10-22 EP EP07821650A patent/EP2076494B1/en active Active
- 2007-10-22 PL PL07821650T patent/PL2076494T3/pl unknown
- 2007-10-22 PT PT07821650T patent/PT2076494E/pt unknown
- 2007-10-22 UA UAA200902359A patent/UA99109C2/ru unknown
- 2007-10-22 EA EA200970398A patent/EA016311B1/ru not_active IP Right Cessation
- 2007-10-22 AT AT07821650T patent/ATE475648T1/de active
- 2007-10-22 US US12/446,580 patent/US8114880B2/en not_active Expired - Fee Related
- 2007-10-22 CN CN2007800393884A patent/CN101528695B/zh not_active Expired - Fee Related
- 2007-10-22 MX MX2009004386A patent/MX2009004386A/es active IP Right Grant
- 2007-10-22 DK DK07821650.4T patent/DK2076494T3/da active
- 2007-10-22 BR BRPI0717357-1A2A patent/BRPI0717357A2/pt not_active IP Right Cessation
- 2007-10-22 SI SI200730371T patent/SI2076494T1/sl unknown
- 2007-10-22 KR KR1020097008396A patent/KR101415536B1/ko not_active Expired - Fee Related
- 2007-10-23 TW TW096139583A patent/TWI396688B/zh not_active IP Right Cessation
- 2007-10-23 CL CL200703042A patent/CL2007003042A1/es unknown
- 2007-10-23 AR ARP070104677A patent/AR063517A1/es not_active Application Discontinuation
-
2009
- 2009-04-23 ZA ZA200902822A patent/ZA200902822B/xx unknown
- 2009-04-23 IL IL198332A patent/IL198332A/en active IP Right Grant
- 2009-05-25 NO NO20092005A patent/NO20092005L/no not_active Application Discontinuation
-
2010
- 2010-10-27 CY CY20101100974T patent/CY1111010T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007003042A1 (es) | Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte | |
| BR112012016398A2 (pt) | Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa | |
| CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
| CL2007002188A1 (es) | Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal. | |
| CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
| UY29675A1 (es) | Nuevos derivados de 1,1-dióxido de 1,4-benzotiazepina con mejores propiedades, procedimiento para su preparacion, medicamentoss que comprenden este compuestoy su uso. | |
| CL2007003187A1 (es) | Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de | |
| CU23614B7 (es) | Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
| BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
| CL2007001869A1 (es) | Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| EA201170772A1 (ru) | Органические соединения | |
| BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
| DOP2011000176A (es) | Compuestos organicos | |
| SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| DOP2011000360A (es) | Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4((2-amino-4-metil-6-(pentilamino) primidin-5-ii)metil) fenil) acetato de 4-(dimetilamino) butilo | |
| BR112012008485A2 (pt) | composto, formulação farmacêutica, uso de um composto, processo para a fabricação do composto de formula e compostos, processos, formulações e usos | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CU23615B7 (es) | Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| BRPI0809661A2 (pt) | Composição farmacêutica estabilizada contendo pregabalina | |
| BRPI1008039A2 (pt) | composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2008002708A1 (es) | Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo, |